Integrated Wealth Concepts LLC increased its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 12.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 128,068 shares of the company’s stock after purchasing an additional 13,850 shares during the period. Integrated Wealth Concepts LLC’s holdings in Merck & Co., Inc. were worth $16,457,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Brighton Jones LLC lifted its holdings in Merck & Co., Inc. by 29.5% in the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after purchasing an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC grew its holdings in Merck & Co., Inc. by 52.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after buying an additional 3,941 shares in the last quarter. Diversify Advisory Services LLC grew its holdings in Merck & Co., Inc. by 94.1% during the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock valued at $2,590,000 after buying an additional 15,636 shares in the last quarter. Diversify Wealth Management LLC raised its position in shares of Merck & Co., Inc. by 22.2% during the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock valued at $3,054,000 after buying an additional 6,897 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Merck & Co., Inc. by 111.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock valued at $53,918,000 after buying an additional 359,356 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.
Insider Buying and Selling
In other Merck & Co., Inc. news, EVP David Maraldo sold 18,706 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the transaction, the executive vice president owned 18,212 shares of the company’s stock, valued at $2,344,248.64. This represents a 50.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Richard Deluca sold 20,784 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $130.43, for a total value of $2,710,857.12. Following the completion of the sale, the executive vice president owned 134,703 shares in the company, valued at approximately $17,569,312.29. The trade was a 13.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 228,238 shares of company stock worth $29,977,783 over the last ninety days. Corporate insiders own 0.17% of the company’s stock.
Trending Headlines about Merck & Co., Inc.
- Positive Sentiment: Analyst upgrades support valuation: Leerink Partners raised its price target from $127 to $161 and maintained an “outperform” rating, while Guggenheim increased its target from $146 to $170 and assigned a “buy” rating. The revisions suggest analysts see further upside from Merck’s commercial execution and pipeline. Benzinga analyst rating reports
- Positive Sentiment: Pipeline expansion addresses the Keytruda patent cliff: Merck is pairing antibody-drug conjugates (ADCs) with Keytruda in women’s cancers, seeking to improve outcomes in difficult-to-treat tumors while building future revenue sources before Keytruda faces patent pressure. Merck pairs ADCs with Keytruda in women’s cancer push
- Neutral Sentiment: Investor attention is focused on management commentary: Merck presented at the Wells Fargo 21st Annual Healthcare Conference and is scheduled to participate in Morgan Stanley’s global healthcare conference. These events may provide additional detail on Keytruda demand, pipeline progress and long-term growth plans. Wells Fargo healthcare conference transcript
- Neutral Sentiment: Keytruda and new products remain central to the bull case: Commentary highlights Keytruda’s current growth contribution and Merck’s efforts to develop products capable of extending momentum beyond the anticipated 2028 patent cliff. MRK’s strong recent performance and elevated valuation leave expectations high. Merck trading near 52-week high
- Negative Sentiment: Long-term patent risk remains: Investors are watching whether Merck can replace revenue that may be lost when Keytruda’s exclusivity weakens. The company’s ability to commercialize ADC combinations and other pipeline assets is therefore critical to sustaining growth and its current valuation. Merck outlook and GARDASIL commentary
Analysts Set New Price Targets
A number of equities analysts recently weighed in on MRK shares. Cantor Fitzgerald restated a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Leerink Partners lifted their price target on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the company an “outperform” rating in a report on Wednesday. UBS Group boosted their price target on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. JPMorgan Chase & Co. increased their price objective on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Finally, Wolfe Research increased their price objective on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a report on Tuesday, August 25th. Sixteen equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $150.33.
Read Our Latest Research Report on Merck & Co., Inc.
Merck & Co., Inc. Stock Performance
Merck & Co., Inc. stock opened at $147.69 on Thursday. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The firm has a market capitalization of $364.37 billion, a P/E ratio of 118.15, a price-to-earnings-growth ratio of 6.46 and a beta of 0.21. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $156.92. The company’s 50-day moving average is $135.91 and its 200 day moving average is $124.10.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Research analysts forecast that Merck & Co., Inc. will post 2.76 EPS for the current year.
Merck & Co., Inc. Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. Merck & Co., Inc.’s payout ratio is presently 272.00%.
Merck & Co., Inc. Profile
Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.
Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.
Read More
- Five stocks we like better than Merck & Co., Inc.
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
